Charles Bankhead is a staff writer for MedPage Today, a leading source of medical news. With a focus on healthcare and medicine, Charles covers a wide range of topics including emerging treatments, clinical challenges, FDA approvals, and advancements in various medical fields. His work has also been featured in Knowledia.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Charles Bankhead's focus is primarily on medical research, clinical trials, FDA approvals, and scientific developments in healthcare and pharmaceuticals. His coverage includes citing data from various studies and press releases.
If you are reaching out to Charles, consider providing insights or commentary based on recent medical research findings or clinical trial outcomes. Expert opinions related to FDA approvals, drug therapies, or challenges in specific areas of healthcare could be well-received by him.
Since his geographic focus is not specified but his topics are broad and universal, pitches can come from experts across the globe who have valuable insights into these areas of medical research and pharmaceuticals.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Charles Bankhead
— More IKCS news: Long-term survival benefit with nivolumab/ipilimumab, disease-slowing surgery
By: Charles Bankhead
— Better OS, PFS, response rate, but newer combination strategies not included
By: Charles Bankhead
— Possible guidance for use of adjuvant immunotherapy in high-risk, non-metastatic disease
— Other IKCS news: closer look at belzutifan safety, challenges of triplet therapies for RCC
By: Charles
News, features, and commentary about cancer-related issues
By: Charles Bankhead
— More than 40% of adults, half of children met response criteria, majority of responses durable
Complete responses in 21% of patients treated with single-agent revumenib
By: Charles Bankhead
— Time for "long goodbye" to the "burning red devil," say editorialists
By: Charles Bankhead
— News, features, and commentary about cancer-related issues A chemotherapy-free regimen opens in a new tab or window of neoadjuvant
By: Charles Bankhead
— Meta-analysis shows better PFS, OS with RT-first approach, but issue requires more study
(833) 317-6278 
